These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1309 related articles for article (PubMed ID: 21888837)

  • 1. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Martin Saborido C; Oyee J; Blundell M; Dundar Y; Dickson R; Proudlove C; Fisher M
    Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
    Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R
    Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK.
    Karnon J; Brennan A; Pandor A; Fowkes G; Lee A; Gray D; Coshall C; Nicholls C; Akehurst R
    Curr Med Res Opin; 2005 Jan; 21(1):101-12. PubMed ID: 15881481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
    Diener HC; Sacco R; Yusuf S; ;
    Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetylsalicylic acid + extended-release dipyridamole combination therapy for secondary stroke prevention.
    Chaturvedi S
    Clin Ther; 2008 Jul; 30(7):1196-205. PubMed ID: 18691981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Sep; 10(5):331-42. PubMed ID: 22853743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty.
    Matchar DB; Samsa GP; Liu S
    Value Health; 2005; 8(5):572-80. PubMed ID: 16176495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.
    Main C; Palmer S; Griffin S; Jones L; Orton V; Sculpher M; Henderson R; Sudlow C; Hawkins N; Riemsma R
    Health Technol Assess; 2004 Oct; 8(40):iii-iv, xv-xvi, 1-141. PubMed ID: 15461878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT.
    Bath PM; Woodhouse LJ; Appleton JP; Beridze M; Christensen H; Dineen RA; Flaherty K; Duley L; England TJ; Havard D; Heptinstall S; James M; Kasonde C; Krishnan K; Markus HS; Montgomery AA; Pocock S; Randall M; Ranta A; Robinson TG; Scutt P; Venables GS; Sprigg N
    Health Technol Assess; 2018 Aug; 22(48):1-76. PubMed ID: 30179153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
    Niu PP; Guo ZN; Jin H; Xing YQ; Yang Y
    BMJ Open; 2016 Mar; 6(3):e009013. PubMed ID: 26988347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
    De Schryver EL; Algra A; van Gijn J
    Cochrane Database Syst Rev; 2003; (1):CD001820. PubMed ID: 12535415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
    Shah H; Gondek K
    Clin Ther; 2000 Mar; 22(3):362-70; discussion 360-1. PubMed ID: 10963290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis.
    Rogowski W; Burch J; Palmer S; Craigs C; Golder S; Woolacott N
    Health Technol Assess; 2009 Jun; 13(31):iii-iv, ix-xi, 1-77. PubMed ID: 19573471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
    Logman JF; Heeg BM; Herlitz J; van Hout BA
    Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study].
    Haldemann R; Lüscher TF; Szucs TD
    Praxis (Bern 1994); 2001 Mar; 90(13):539-45. PubMed ID: 11550619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The value of platelet inhibitors in the secondary prophylaxis of stroke -- a review].
    Schellinger PD; Jüttler E; Meyding-Lamadé UK; Schwark C
    Fortschr Neurol Psychiatr; 2004 May; 72(5):270-81. PubMed ID: 15136948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and costs of secondary prevention with antiplatelets after ischaemic stroke.
    Ringleb PA; Schwark C; Schwaninger M; Schellinger PD
    Expert Opin Pharmacother; 2005 Mar; 6(3):359-67. PubMed ID: 15794727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease.
    Aronow WS
    Drugs Aging; 1999 Aug; 15(2):91-101. PubMed ID: 10495069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
    Schleinitz MD; Weiss JP; Owens DK
    Am J Med; 2004 Jun; 116(12):797-806. PubMed ID: 15178495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Pouwels XGLV; Wolff R; Ramaekers BLT; Van Giessen A; Lang S; Ryder S; Worthy G; Duffy S; Armstrong N; Kleijnen J; Joore MA
    Pharmacoeconomics; 2018 May; 36(5):533-543. PubMed ID: 29344794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.